- Dr. Kline will join Innocan’s R&D team
- Dr. Kline is a board-certified, surgical and clinical dermatologist
- Dr Kline has served on the boards of several leading organizations
- Innocan is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol
- Innocan Pharma Ltd. (INNO) opened is trading at C$0.35 per share
Innocan Pharma Corporation (INNO) is proud to announce the addition of Dr. Mitchell Kline to its Scientific Advisory Committee.
Dr. Kline will use his extensive experience in researching and treating different skin conditions to further develop Innocan’s derma cosmetic line.
Dr. Kline is a board-certified, fellowship-trained surgical and clinical dermatologist.
Dr. Kline is currently acting as the Principal Clinician at Kline Dermatology and the Clinical Assistant Instructor of Dermatology at Weill Cornell Medical College.
He has published several articles, holds 23 organizational memberships, has generated five research and concept proposals, and has participated in over 14 grand rounds presentations.
Dr Kline has served on the boards of leading organizations including Healthright International, Whitehead Institute-MIT, American Academy of Dermatology, Dermatology Foundation, New York Academy of Sciences and the American Society for Dermatologic Surgery.
Dr Kline was awarded the Humanitarian Award of the Melanoma Research Foundation.
Dr. Kline said,
“Working with Innocan will provide a platform and an opportunity to bring innovative delivery and anti-inflammatory technologies to the wellness and cosmetics industries. I look forward to collaborating with Innocan to develop unprecedented CBD-based treatments to meet the needs of all patients.”
Iris Bincovich, Innocan’s CEO, said,
“We are deeply humbled to have been able to add Dr. Kline to our Scientific Advisory Committee. The next few months may result in some major developments and Dr. Kline’s ability to help us deliver these promises is significant.”
Innocan, through its wholly-owned Israeli subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol.
Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets the Covid-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells.
Innocan Pharma Ltd. (INNO) opened is trading at C$0.35 per share.
